Raymond James Initiates Coverage on Insmed with Outperform Rating
On April 9, 2026, Raymond James initiated coverage of Insmed (NASDAQ:INSM) with an 'Outperform' rating and a $200 price target. The firm cited the early success of Brinsupri as having de-risked the company's trajectory in inflammation and immunology markets due to limited competition.
Tickers: $INSM